February 25th 2025
Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
Mistrust of medical research may discourage genetic testing in prostate cancer
November 20th 2023According to the survey, 79% of Black men know that genetic information can help improve prostate cancer outcomes, yet 33% indicated that they would be unwilling or uncertain to provide DNA samples, even if it meant finding new treatment options.
Genomics and other tools enhance precision of active surveillance in prostate cancer
November 7th 2023"All of our tools, including genomics and MRI, enable us to do a better job of risk stratifying [patients] to have a more appropriate shared decision-making discussion [about active surveillance]," explains David Morris, MD.
ctDNA shows promise for clinical staging in patients with upper tract urothelial carcinoma
October 20th 2023“This is the first study in upper tract urothelial carcinoma to show that ctDNA may be used to refine clinical staging and prognosis in these patients prior to surgery,” says Heather L. Huelster, MD.
Investigators evaluate ctDNA for predicting muscle-invasive and non–organ-confined staging of UTUC
October 18th 2023"In this study, we sought to evaluate the utility of a non-invasive biomarker—ctDNA—in predicting muscle-invasive and non–organ-confined staging of upper tract urothelial carcinoma," says Heather L. Huelster, MD.
Molecular insights from study may yield new prostate cancer treatment strategies
October 17th 2023“Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions,” said Zhijie “Jason” Liu, PhD.
FDA allows marketing of genetic test for predisposition to several cancers, including prostate
October 11th 2023The Invitae Common Hereditary Cancers Panel utilizes DNA taken from a blood sample to identify the presence of variants in 47 genes linked to an increased risk of developing certain cancers.
Dr. Alumkal on FDA approval of talazoparib/enzalutamide for HRR gene–mutated mCRPC
September 6th 2023Joshi Alumkal, MD, discusses the phase 3 TALAPRO-2 trial, which supported the FDA approval of the combination of talazoparib and enzalutamide for patients with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination repair gene defects.
Olaparib/abiraterone regimen approved in Japan for BRCA-positive mCRPC
August 24th 2023The approval of the olaparib/abiraterone regimen was based on an exploratory subgroup analysis of the phase 3 PROpel trial consisting of the 85 patients in the study with BRCA-positive metastatic castration-resistant prostate cancer.